Literature DB >> 31204177

Antibody Conditioning Enables MHC-Mismatched Hematopoietic Stem Cell Transplants and Organ Graft Tolerance.

Benson M George1, Kevin S Kao1, Hye-Sook Kwon2, Brenda J Velasco2, Jessica Poyser2, Angela Chen3, Alan C Le2, Akanksha Chhabra2, Cassandra E Burnett2, Devon Cajuste4, Malachia Hoover4, Kyle M Loh3, Judith A Shizuru5, Irving L Weissman6.   

Abstract

Hematopoietic cell transplantation can correct hematological and immunological disorders by replacing a diseased blood system with a healthy one, but this currently requires depleting a patient's existing hematopoietic system with toxic and non-specific chemotherapy, radiation, or both. Here we report an antibody-based conditioning protocol with reduced toxicity and enhanced specificity for robust hematopoietic stem cell (HSC) transplantation and engraftment in recipient mice. Host pre-treatment with six monoclonal antibodies targeting CD47, T cells, NK cells, and HSCs followed by donor HSC transplantation enabled stable hematopoietic system reconstitution in recipients with mismatches at half (haploidentical) or all major histocompatibility complex (MHC) genes. This approach allowed tolerance to heart tissue from HSC donor strains in haploidentical recipients, showing potential applications for solid organ transplantation without immune suppression. Fully mismatched chimeric mice developed antibody responses to nominal antigens, showing preserved functional immunity. These findings suggest approaches for transplanting immunologically mismatched HSCs and solid organs with limited toxicity.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  conditioning; hematopoietic stem cell; immunosuppression; major histocompatibility complex mismatch; organ transplantation; stem cell transplantation; tolerance

Year:  2019        PMID: 31204177      PMCID: PMC6679784          DOI: 10.1016/j.stem.2019.05.018

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  71 in total

1.  Direct isolation of human central nervous system stem cells.

Authors:  N Uchida; D W Buck; D He; M J Reitsma; M Masek; T V Phan; A S Tsukamoto; F H Gage; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.

Authors:  T Kawai; D Andrews; R B Colvin; D H Sachs; A B Cosimi
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 3.  Stem cells: units of development, units of regeneration, and units in evolution.

Authors:  I L Weissman
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

4.  Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection.

Authors:  J A Shizuru; I L Weissman; R Kernoff; M Masek; Y C Scheffold
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

5.  CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers.

Authors:  K L Gandy; J Domen; H Aguila; I L Weissman
Journal:  Immunity       Date:  1999-11       Impact factor: 31.745

6.  Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.

Authors:  T Wekerle; J Kurtz; H Ito; J V Ronquillo; V Dong; G Zhao; J Shaffer; M H Sayegh; M Sykes
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

7.  Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.

Authors:  R S Negrin; K Atkinson; T Leemhuis; E Hanania; C Juttner; K Tierney; W W Hu; L J Johnston; J A Shizurn; K E Stockerl-Goldstein; K G Blume; I L Weissman; S Bower; R Baynes; R Dansey; C Karanes; W Peters; J Klein
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

8.  A novel application of cyclosporine A in nonmyeloablative pretransplant host conditioning for allogeneic BMT.

Authors:  B Nikolic; G Zhao; K Swenson; M Sykes
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

9.  Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning.

Authors:  M M Durham; A W Bingaman; A B Adams; J Ha; S Y Waitze; T C Pearson; C P Larsen
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

10.  Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.

Authors:  Thomas R Spitzer; Steven L McAfee; Bimalangshu R Dey; Christine Colby; James Hope; Howard Grossberg; Frederic Preffer; Juanita Shaffer; Stephen I Alexander; David H Sachs; Megan Sykes
Journal:  Transplantation       Date:  2003-05-27       Impact factor: 4.939

View more
  23 in total

Review 1.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

Review 2.  The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease.

Authors:  Motoko Koyama; Geoffrey R Hill
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

3.  Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.

Authors:  Matthew M Hsieh; Melissa Bonner; Francis John Pierciey; Naoya Uchida; James Rottman; Laura Demopoulos; Manfred Schmidt; Julie Kanter; Mark C Walters; Alexis A Thompson; Mohammed Asmal; John F Tisdale
Journal:  Blood Adv       Date:  2020-05-12

Review 4.  The CD47-SIRPα Immune Checkpoint.

Authors:  Meike E W Logtenberg; Ferenc A Scheeren; Ton N Schumacher
Journal:  Immunity       Date:  2020-05-19       Impact factor: 31.745

5.  Skeletal Stem Cells as the Developmental Origin of Cellular Niches for Hematopoietic Stem and Progenitor Cells.

Authors:  Thomas H Ambrosi; Charles K F Chan
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

6.  CD45: a niche marker for allotransplantation.

Authors:  Zhanzhuo Li; Philip M Murphy
Journal:  Blood       Date:  2022-03-17       Impact factor: 22.113

7.  Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.

Authors:  Stephen P Persaud; Julie K Ritchey; Sena Kim; Sora Lim; Peter G Ruminski; Matthew L Cooper; Michael P Rettig; Jaebok Choi; John F DiPersio
Journal:  J Clin Invest       Date:  2021-12-15       Impact factor: 14.808

8.  A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.

Authors:  Asim Saha; Sharon Hyzy; Tahirih Lamothe; Katelyn Hammond; Nicholas Clark; Leanne Lanieri; Prashant Bhattarai; Rahul Palchaudhuri; Geoffrey O Gillard; Jennifer Proctor; Megan J Riddle; Angela Panoskaltsis-Mortari; Margaret L MacMillan; John E Wagner; Hans-Peter Kiem; Lisa M Olson; Bruce R Blazar
Journal:  Blood       Date:  2022-03-17       Impact factor: 22.113

9.  5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.

Authors:  Andriyana K Bankova; Wendy W Pang; Brenda J Velasco; Janel R Long-Boyle; Judith A Shizuru
Journal:  Blood Adv       Date:  2021-10-12

10.  Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development.

Authors:  Paula Cannon; Aravind Asokan; Agnieszka Czechowicz; Paula Hammond; Donald B Kohn; Andre Lieber; Punam Malik; Peter Marks; Matthew Porteus; Els Verhoeyen; Drew Weissman; Irving Weissman; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2021-01       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.